Search Results for: Influenza

856 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
E2F5 and TFDP1 E2F transcription factor 5 transcription factor Dp-1
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • G0 and Early G1
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • Cyclin A:Cdk2-associated events at S phase entry
  • Activation of NOXA and translocation to mitochondria
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • Activation of PUMA and translocation to mitochondria
  • G0 and Early G1
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by E2F6
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
E2F6 and TFDP1 E2F transcription factor 6 transcription factor Dp-1
  • G1/S-Specific Transcription
  • Transcriptional Regulation by E2F6
  • Activation of NOXA and translocation to mitochondria
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by DREAM complex
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • Activation of PUMA and translocation to mitochondria
  • G0 and Early G1
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Cyclin E associated events during G1/S transition
  • G1/S-Specific Transcription
  • G1/S-Specific Transcription
  • Cyclin D associated events in G1
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by E2F6
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
ECT2 and FANCM epithelial cell transforming 2 FA complementation group M
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • G alpha (12/13) signalling events
  • Fanconi Anemia Pathway
  • Fanconi anemia
PHC2 and L3MBTL3 polyhomeotic homolog 2 L3MBTL histone methyl-lysine binding protein 3
  • Oxidative Stress Induced Senescence
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription cofactors
  • SUMOylation of chromatin organization proteins
  • SUMOylation of RNA binding proteins
  • SUMOylation of DNA methylation proteins
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
EEF1G and LZTS1 eukaryotic translation elongation factor 1 gamma leucine zipper tumor suppressor 1
  • Eukaryotic Translation Elongation
EGF and ADAM12 epidermal growth factor ADAM metallopeptidase domain 12
  • Platelet degranulation
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Downregulation of ERBB2 signaling
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by EGFR
  • Invadopodia formation
  • Sucralfate
  • Alpha-Aminobutyric Acid
  • Tesevatinib
  • Gastric cancer
EGFR and B4GALT1 epidermal growth factor receptor beta-1,4-galactosyltransferase 1
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Pre-NOTCH Processing in Golgi
  • Keratan sulfate biosynthesis
  • Interaction With Cumulus Cells And The Zona Pellucida
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
  • Lactose synthesis
  • Neutrophil degranulation
  • N-Glycan antennae elongation
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • N-Acetylglucosamine
  • 6-Aminohexyl-Uridine-C1,5'-Diphosphate
  • Di(N-Acetyl-D-Glucosamine)
  • Galactose-uridine-5'-diphosphate
  • Uridine monophosphate
  • 2-(N-Morpholino)-Ethanesulfonic Acid
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
  • Congenital disorders of glycosylation (CDG) type II
EGFR and PTPRR epidermal growth factor receptor protein tyrosine phosphatase receptor type R
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
EGFR and TMCO3 epidermal growth factor receptor transmembrane and coiled-coil domains 3
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
EGFR and PDCD6IP epidermal growth factor receptor programmed cell death 6 interacting protein
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Budding and maturation of HIV virion
  • Uptake and function of anthrax toxins
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
EPHA2 and PTPRR EPH receptor A2 protein tyrosine phosphatase receptor type R
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Dasatinib
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Regorafenib
ENG and TGFB1 endoglin transforming growth factor beta 1
  • Platelet degranulation
  • Influenza Virus Induced Apoptosis
  • Cell surface interactions at the vascular wall
  • Molecules associated with elastic fibres
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • Syndecan interactions
  • ECM proteoglycans
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • Transcriptional regulation of white adipocyte differentiation
  • UCH proteinases
  • Interleukin-4 and Interleukin-13 signaling
  • RUNX3 regulates CDKN1A transcription
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • Hyaluronidase
  • Hyaluronidase (Human Recombinant)
  • Hereditary hemorrhagic telangiectasia (HHT)
  • Graft-versus-host disease
  • Allograft rejection
  • Camurati-Engelmann disease; Progressive diaphyseal dysplasia
EP300 and MITF E1A binding protein p300 melanocyte inducing transcription factor
  • Regulation of gene expression by Hypoxia-inducible Factor
  • RORA activates gene expression
  • RORA activates gene expression
  • Polo-like kinase mediated events
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Circadian Clock
  • Circadian Clock
  • B-WICH complex positively regulates rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • Metalloprotease DUBs
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • SUMOylation of transcription factors
  • Rubinstein-Taybi syndrome
  • Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
  • Waardenburg syndrome (WS)
  • Malignant melanoma
EPB41 and NUMA1 erythrocyte membrane protein band 4.1 nuclear mitotic apparatus protein 1
  • Neurexins and neuroligins
  • Recruitment of NuMA to mitotic centrosomes
  • Mitotic Prophase
  • Hereditary elliptocytosis (HE)
EPB41L1 and NUMA1 erythrocyte membrane protein band 4.1 like 1 nuclear mitotic apparatus protein 1
  • Trafficking of AMPA receptors
  • Neurexins and neuroligins
  • Recruitment of NuMA to mitotic centrosomes
  • Mitotic Prophase
EPB41L2 and NUMA1 erythrocyte membrane protein band 4.1 like 2 nuclear mitotic apparatus protein 1
  • Neurexins and neuroligins
  • Recruitment of NuMA to mitotic centrosomes
  • Mitotic Prophase
EPHB2 and MMP9 EPH receptor B2 matrix metallopeptidase 9
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • L1CAM interactions
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Signaling by SCF-KIT
  • Collagen degradation
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Assembly of collagen fibrils and other multimeric structures
  • EPH-ephrin mediated repulsion of cells
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • Extra-nuclear estrogen signaling
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Glutathione
  • Marimastat
  • Minocycline
  • Captopril
  • Glucosamine
  • Zinc
  • 2-Amino-N,3,3-Trimethylbutanamide
  • 2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid
  • AE-941
  • PG-530742
  • 5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE
  • (2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE
  • (3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID
  • Penile cancer
  • Metaphyseal dysplasias, including: Metaphyseal dysplasia, Schmid type; Metaphyseal dysplasia, McKusik type; Metaphyseal dysplasia, Jansen type; Shwachman-Bodian-Diamond syndrome (SBDS); Metaphyseal anadysplasia (MAD)
EPS15 and AGFG1 epidermal growth factor receptor pathway substrate 15 ArfGAP with FG repeats 1
  • EGFR downregulation
  • Negative regulation of MET activity
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
ERBB2 and PTPRR erb-b2 receptor tyrosine kinase 2 protein tyrosine phosphatase receptor type R
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Brigatinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
ERBB3 and PTPRR erb-b2 receptor tyrosine kinase 3 protein tyrosine phosphatase receptor type R
  • Lethal congenital contractural syndrome (LCCS)
  • Type I diabetes mellitus

Page 20 out of 43 pages